Stay updated with breaking news from Herlev. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Nordic Bioscience, a leading biomarker company, today announced that the internationally recognized New England Journal of Medicine Evidence...
Based on data from a randomized trial presented at ESMO, the Netherlands Cancer Institute is exploring the possibility of seeking regulatory approval for TIL therapy without pharma involvement.
A novel cell therapy made from tumor infiltrating lymphocytes (TILs) was superior to ipilimumab, and may be a new treatment option for advanced stage melanoma.
Use of treatments to increase low plasma potassium levels may decrease the burden of arrhythmia in high-risk patients with cardiovascular disease.
While underpowered to show clinical benefits, the trial hints at the possibility of fewer hospitalizations and deaths.